Morgan Crucible Co PLC
06 May 2005
The Morgan Crucible Company plc
The Company was informed on 6 May 2004, that the Trustees of The Morgan General
Employee Benefit Trust ('the Trust') acquired 2,000,000 (two million) ordinary
shares in the capital of the Company at an average price of £1.744464 per share
to satisfy future obligations arising from provisional awards made under The
Morgan Crucible Long Term Incentive Plan 2004 and share options granted under
The Morgan Crucible Executive Share Option Scheme 2004.
Following this purchase, the Trust holds a total of 4,720,080 ordinary shares
representing 1.626% of the share capital of the Company. The class of
discretionary beneficiaries for whom the Trust holds such shares consists of
employees of the Company including executive directors Warren Decatur Knowlton,
Mark Robertshaw, Hartmut Eisele and Mark Lejman and these directors are
accordingly deemed to be beneficially interested in all of such shares held by
the Trust.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.